skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.10e (Release date: 2017-10-30)
SearchBox Top
SearchBox Bottom
Deferasirox (Code C48384)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Deferasirox

Definition: A synthetic, orally bioavailable, achiral, tridentate triazole derived from salicylic acid with iron-chelating activity. Deferasirox chelates iron at a 2:1 (ligand:iron) ratio. Because of its oral availability and long plasma half-life, this agent may be superior to desferrioxamine (desferal, DFO), which is orally inactive and has a short plasma half-life.

NCI-GLOSS Definition: A drug used to treat too much iron in the blood caused by blood transfusions. It is being studied in the treatment of myelodysplastic syndromes (a group of diseases in which the bone marrow does not make enough healthy blood cells) and other conditions. Deferasirox binds to extra iron in the blood. The drug and the iron are passed from the body in urine. It is a type of chelating agent.

Display Name: Deferasirox

Label: Deferasirox

NCI Thesaurus Code: C48384 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: C1619629  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
4-(3,5-Bis-(hydroxy-phenyl)-1,2,4-triazol-1-yl)-benzoic Acid

External Source Codes: 
CAS Registry Number 201530-41-8 (see NLM ChemIDplus info)
ChEBI ID CHEBI:49005 (see ChEBI info)
PDQ Closed Trial Search ID 435986
PDQ Open Trial Search ID 435986 (check for NCI PDQ open clinical trial info)
UMLS CUI C1619629

Other Properties:
     Name Value (qualifiers indented underneath)
Chemical_Formula C21H15N3O4
code C48384
Contributing_Source CTRP
Contributing_Source FDA
Legacy_Concept_Name Deferasirox
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom